School of Pharmaceutical Science, Key Laboratory of Chemical Biology, Ministry of Education, Shandong University, Jinan 250012, China.
Key Lab of Colloid & Interface Chemistry, Shandong University, Ministry of Education, Jinan 250100, China.
J Colloid Interface Sci. 2019 Jul 1;547:30-39. doi: 10.1016/j.jcis.2019.03.087. Epub 2019 Mar 26.
Chemo-photodynamic therapy is an attractive strategy against cancer. However, the combination of chemotherapeutic agent and photosensitizer is usually realized by physically embedding one or two agents in the carriers. In this case, batch to batch variation of drug contents increases the risk of composition uncertainty, limiting the clinical application of currently developed chemo-photodynamic therapy. Therefore, it is highly desirable for constructing chemo-photodynamic therapy nanoplatform with precisely controllable composition and drug loading content. Here, a precise chemo-photodynamic therapy nanoplatform is reported based on the chemical conjugation of both doxorubicin (DOX) and photosensitizer chlorin e6 (Ce6) to active targeting hyaluronic acid (HA). The achieved HA-DOX-Ce6 (HDC) conjugate can self-assemble into all-in-one nanoparticles (NPs) with properties of pH-response, self-targeting delivery, near-infrared (NIR) fluorescence imaging and chemo-photodynamic combination therapy. Because HDC conjugate holds precise components, the HDC NPs have a constant composition and drug loading content, endowing a precise chemo-photodynamic therapy nanoplatform. The HDC NPs show significantly higher cellular uptake and remarkably better tumor-targeted accumulation than free drugs. Moreover, HDC NPs with the laser irradiation exhibit enhanced anticancer activities both in vitro and in vivo. This work may open the door for design of all-in-one advanced nanoplatform toward chemo-photodynamic therapy with precisely controllable composition and drug loading content.
化学-光动力疗法是一种有吸引力的抗癌策略。然而,化疗药物和光敏剂的组合通常通过将一种或两种药物物理嵌入载体中来实现。在这种情况下,药物含量的批间变化增加了成分不确定性的风险,限制了目前开发的化学-光动力疗法的临床应用。因此,构建具有精确可控成分和载药量的化学-光动力治疗纳米平台是非常理想的。在这里,报道了一种基于阿霉素(DOX)和光敏剂氯己定(Ce6)与主动靶向透明质酸(HA)的化学偶联构建精确化学-光动力治疗纳米平台的方法。所得到的 HA-DOX-Ce6(HDC)缀合物可以自组装成具有 pH 响应、自靶向递药、近红外(NIR)荧光成像和化学-光动力联合治疗功能的一体化纳米颗粒(NPs)。由于 HDC 缀合物具有精确的成分,HDC NPs 具有恒定的组成和载药量,赋予了精确的化学-光动力治疗纳米平台。与游离药物相比,HDC NPs 具有更高的细胞摄取率和更好的肿瘤靶向积累。此外,激光照射下的 HDC NPs 在体外和体内均表现出增强的抗癌活性。这项工作为设计具有精确可控成分和载药量的一体化先进纳米平台用于化学-光动力治疗开辟了道路。